Abstract

The incidence of solitary thyroid lesions are more common now a days. There is a chance of increase in malignancy rate especially in solitary nodules. Always there will be diagnostic dilemma in differentiating benign and malignant lesions. Our study mainly focused to find the expression of galectin 3 in differential diagnosis of solitary thyroid lesions in a teritiary care hospital for a period of 2 years.

• 1.   Ashcroft M W,Van Herle AJ Management of thyroid nodules .I Head, neck surgery 1981:3:216-230
• 2.   Ahmed I ,Malik ML, Ashraf M,. Pattern of malignancy in solitary thyroid nodule.Biomedia 1999:15:39-42
• 3.   Rahul Chetan V, Veerealingam B, Kishore kumar M, Prabhas Teja Durbesula,Pasupuleti Sreenivasa Rao, A Study on the clinical manifestations and the incidence of benign and malignant tumors in asolitary thyroid nodule. Int J Res Med Sci 2013nov:1(4);429-434
• 4.   Robinson E, Horn Y, Hochmann A.Incidence of cancer in thyroid nodule. Surg Gynecol obstet 1966:123:1024-26
• 5.   Inhora H.Raz.A. Functional evidence that cell surface galectin3 mediates homotypic cell adhesion. Cancer Res 1995;55;3267-3271
• 6.   Lei gong,Ping chen Xianjun Liu et al,expression of D2-40,CK19 ,Galectin3, VEGF and EGFR in papillary carcinoma, Gland surgery 2012;1(1)25-32
• 7.   Psarras A et al. The single thyroid nodule.Br J Surg 1972;59(7);545-548
• 8.   Nagori L.F,Algotar MJ., Solitary thyroid nodule Ind J Surg 1992;54(2);75-78
• 9.   Ananthakrishnan N,Rao KM,Narasimhan R, Veliath AJ. Single thyroid nodule. South Indian profile of 503 cases with special reference incidenceof malignancy.Ind J Surg 1993;55(10)487-92
• 10.   Khadilkar UNL, Maji P,Histopathological study of solitary nodules of thyroid, Kathmandu university medical journal 2008;vol6;issue24, no4,486-490
• 11.   Tsegaye B,Ergete W,Histopathological pattern of thyroid disease. East African med J 2003;80;(10);525-528
• 12.   El-kateb M I, Magdy I, Ahmed,Samah S,Mohammed and Mona S, Mostafa. Evaluation of thyroid nodules using TPO and galectin 3;an immunohistochemical study.ZUMJ 1013,vol 19;4;530-537
• 13.   Beesley F, Mc Lauren M, cytokeratin ad and galectin 3 ihc in differential diagnosis of solitary thyroid nodules,histopathology 2002;41;236-243
• 14.   Qingbin Song,Deguang Wang,Yi Lou,Changs Li, Changqing Fang,Xiangmin He and Jianhua Li; Diagnostic significance of CK 19,TG, Ki67 and galectin3 for papillary thyroid carcinoma in the northeast region of china,Diagnistic pathology 2011;6;126
• 15.   Dusko Dundereovic,Jasmina Markovic Lipkovski,Ivan Soldatovic et al,defining the value of CD56,CK19, Galectin 3 and HBME1 in the diagnosis of follicular cell derived lesions of thyroid with systematic review of literature,Diagnostic pathology,2015;10;196
• 16.   Rita Beata kovacs,janos foldes, Gabor Winkler, Miklos Bodo, Zoltan , the investigation of galectin 3 in diseases of thyroid gland, European journal of endocrinology 2003;149;449-453
• 17.   Marie Rydlova,Marie Ludvikova, Ivana stankova; potential diagnostic marker in nodular lesions of the thyroid gland; AN IHC study, Biomed 2008,152(1);53-60
• 18.   Saleh A,Bo J,John B et al, utility of immunohistochemical markers in differentiating benign from malignant follicular derived thyroid nodules,Diagnostic pathology 2010,5:9
• 19.   Hann Alsaeid Alshenawy,utility of ihc markers in differential diagnosis of follicular derived thyroid lesions.journal of microscopy and ultrastructure 2(2014) 127-136
• 20.   Fonseca E,Nesland JM,Hoie J,et al. patterns of expression of cytokeratins filaments in the thyroid gland, immunohistochemical study of simple and stratified epithelial type cytokeratins;Virchows Arch 1997;430;239-246
• 21.   Dockhorn-Dworniczak B,Frank WW, Schroder S et al,pettern of cytoskeletal proteins in human thyroid gland and thyroid carcinoma.Differentiation 1987;35;53-71
• 22.   Kishore n, srivatshava A, Sharma LK, et al.Thyroid neoplasm, A profile; aInd J Surg 1996;56;143-148
• 23.   Cvejic d, savin S et al Differential expression of galectin 3 in papillary projectios of malignant and non malignant hyperplastic thyroid lesions .Acta Chir Iugosl 2003;50;67-70
• 24.   Gasberri A,Martegani P,Del prete F, et al. Galectin3 and CD44v6 isoforms in preoperative evaluation of thyroid nodules.J Clin Oncol 1999;17;3494-02
• 25.   Inhora H, Segawa T ,Miyauchi et al, cytoplasmic and serum galectin3 in diagnosis of thyroid malignancies. Biochem Biophys 2008,376;605-610
• 26.   Fernandez L,Merino J,Gomez M et al ,Galectin3 and laminin expression in neoplastic and non neoplastic thyroid lesions. J Pathol 1997,86(11) 180-6
• 27.   Prasad L,Pellegata S,Huang Y et al Galectins, fibronectin1 Cited 1, HBME-1 and CK19 IHC is useful for the diagnosis of thyroid tumors, Mod Pathol 2005;18:48-57
• 28.   Bartolazzi A, Orlandi F,Saggiorato E et al ;Galectin 3 expression analysis in the surgical selection of follicular thyroid nodules with indeterminate FNAC ,A prospective multicentre study.Lanncet Oncol 2008;9;543-49
• 29.   Pilotti S, Collini P,Marini L et al.Insular carcinoma.a adistinct de novo entity among follicular carcinoma of the thyroid gland;Am J Surg pathol, 1997;21(12);1466-73
• 30.   Volante M,Landolfi S,Chiusa L, Palestini N,Papotti MG.Poorly differentiated carcinoma of thr thyroid with trabecular, insular and solid patterns.A Clincopathologic study of 183 cases. Cancer 2004;100(5);950-957
• 31.   Carol c.Cheung, Shereen Ezaat, Jeremy L,Freeman,Irving B,Rosen,Sylvis L,Asa. Immunohistochemical diagnosis of papillary thyroid carcinoma,modern pathology 2001;14(4)338-342
• 32.   Debdas bose,ram narayan das,uttara chatterjee ,uma Banjerjee.Ck 19 immunohistochemistry in the diagnosis of papillary thyroid carcinoma, Indian journal of medical and pediatric oncology apr-jun 2012 vol33 issue2 ;107-111
• 33.   Kovacs RB, Foldes J,Winnkler J.the investigation of gelectin3 in diseases of the thyroid gland;Eur j Endocrinol 2003;149;1644-50
• 34.   Casey MB.Loshe CM, Lloyd RV; Distinction between papillary thyroid hyperplasia and papillary carcinoma by IHC staining for CK 19 Galectin3 and HBME1 .Endocr Pathol 2003;14;55-60
• 35.   Wu G,Wang J.Zhou Z,Li T,Tang F, Combined staining for ihc markers in the diagnosis of papillary carcinoms;improvement in the specificity or sensitivity? J Int Med Res 2013;41;975-983
• 36.   Saussez S,Glinoer D,Chantrain G, Pattou F et al Serum galectin1 and galectin3 levels in the benign and malignant nodular thyroid disease.Thyroid 2008 ;18;705-712
• 37.   Zhu X,Sun T, Lu H, Zhou X, Lu Y,Cai X, ZHU X,Diagnostic significance of CK19,RET,Galectin3 and HBME-1expression of papillary thyroid carcinoma.J Clini Pathol 2010;63;786-789
• 38.   Barut F,Onak N,Bektas S, Bahadir B,Keser S, U niversal markers of thyroid malignancies;galectin3 CK19,HBME-1.Endocr Pathol 2010;21;80-89
• 39.   Rossi ED,Raffaelli M,Mule A, Lombardi CP, Vecchio FM, Simultaneous IHC expression of HBME-1, Galectin 3 differentiates papillary carcinoma from hyperfunctioning lesions of thyroid;histopathology 2006;48.;795-800

Data Sharing Statement

Funding